Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.83 |
| ▸ | HPGD | P15428 | 6/20 | 0.83 |
| ▸ | CA2 | P00918 | 5/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | CA4 | P22748 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | CA12 | O43570 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.83 |
| ▸ | EGFR | P00533 | 2/20 | 0.83 |
| ▸ | FYN | P06241 | 2/20 | 0.83 |
| ▸ | MMP9 | P14780 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.83 |
| ▸ | NPC1 | O15118 | 2/20 | 0.83 |
| ▸ | GMNN | O75496 | 1/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Catechol SCHEMBL30088487 | 0.91 | — | — | |
| Catechol SCHEMBL367675 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HPGDCA2KDM4EHSD17B10 | |
| Catechol SCHEMBL29352716 | 0.91 | — | — | |
| Catechol SCHEMBL30944695 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HPGDCA2KDM4EHSD17B10 | |
| Catechol SCHEMBL11672589 | 0.91 | ALDH1A1 (1.00) | ALDH1A1HPGDCA2KDM4EHSD17B10 | |
| Catechol SCHEMBL18351 | 0.91 | — | — | |
| Catechol SCHEMBL7871860 | 0.88 | ALDH1A1 (0.77) | ALDH1A1HPGDCA2KDM4EHSD17B10 | |
| Catechol SCHEMBL25313512 | 0.87 | — | — | |
| Catechol SCHEMBL20597824 | 0.87 | — | — | |
| Catechol SCHEMBL11685113 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045486-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | THE PENN STATE RESEARCH FOUNDATION | 2016-02-18 | — | — | US | disclosed |
| EP-2364317-A2 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | Effipharma, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110190332-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | EFFIPHARMA (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010017093-A2 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | EFFIPHARMA, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-0777655-B1 | PROCESS FOR PREPARING CHIRAL TETRACYCLIC DOPAMINERGIC COMPOUNDS | ABBOTT LAB (US) | 2001-01-10 | — | — | EP | disclosed |
| US-5659037-A | FROM VERATROL DERIVATIVE CHIRAL STARTING MATERIAL USING SERIES OF CHIRAL-PRESERVING REACTIONS | ABBOTT LABORATORIES (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0777655-A1 | PROCESS FOR PREPARING CHIRAL TETRACYCLIC DOPAMINERGIC COMPOUNDS | Abbott Laboratories (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5621133-A | PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES | DENINNO MICHAEL P (US) | 1997-04-15 | — | — | US | disclosed |
| US-5591884-A | PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996038435-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996006085-A1 | PROCESS FOR PREPARING CHIRAL TETRACYCLIC DOPAMINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4994486-A | Neurological disorders | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190332-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | PRLHR, OPRD1, SLC6A3 | ALDH1A1 1298/4885HPGD 1391/4885CA2 4649/4885 |
| US-20160045486-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | PRLHR, OPRD1, SLC6A3 | ALDH1A1 1298/4885HPGD 1391/4885CA2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.